Veralox Therapeutics Announces IND Submission for VLX-1005 to Treat...

Initiation of a Phase 1 clinical trial of VLX-1005(PRWeb January 14, 2021)Read the full story at https://www.prweb.com/releases/veralox_therapeutics_announces_ind_submission_for_vlx_1005_to_treat_heparin_inducted_thrombocytopenia/prweb17657995.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news